Key result
Platelet transfusions during emergency CABG after abciximab use are described in a small case series.
Why the study?
The appropriate management of patients who have received abciximab and require emergency coronary artery bypass surgery after failed coronary angioplasty is undetermined.
Does platelet transfusion improve outcomes in patients undergoing emergency coronary bypass surgery after receiving abciximab?
Case Report
Does platelet transfusion improve outcomes in patients undergoing emergency coronary bypass surgery after receiving abciximab?
This case series describes the management and outcomes of using platelet transfusions in patients requiring emergency CABG after failed angioplasty with prior abciximab administration.
Answers are grounded in this paper and cite their sources.
Should not change practice in abciximab-exposed emergency CABG; hypothesis-generating case series leaves optimal strategy open.
Abciximab has been shown to reduce the ischemic complications of high-risk angioplasty procedures. The appropriate management of patients who have received abciximab and require emergency coronary artery bypass surgery after failed coronary angioplasty is as yet undetermined. We present the outcomes of a small series of such patients who were given platelet transfusions before or during cardiopulmonary bypass.
No takes yet. Share an insight, caveat, or question.
Juergens et al. (1997) conducted a case report in Emergency coronary artery bypass surgery after failed coronary angioplasty with prior abciximab. Platelet transfusion was evaluated. A small series described outcomes of platelet transfusions before or during cardiopulmonary bypass in patients requiring emergency CABG after failed angioplasty with prior abciximab.
Synapse has enriched 10 related papers. Consider them for comparative context: